In pursuit of accessible sickle cell cure, Novartis inks $1.5B deal to tap Precision's ARCUS gene editing tech
Novartis brought in another biotech partner on its quest to create an in vivo gene editing therapy for sickle cell disease and other similar blood disorders.
Tapping Precision BioSciences’ ARCUS genome editing platform, Novartis will hand over $75 million upfront to develop a custom ARCUS nuclease that can be used to insert a target transgene at a specific location in the genome. According to the companies, it could become an option for a number of hemoglobinopathies such as beta thalassemia.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.